Antagonists against TNFR1 and methods of use therefor
US9028822B2 · kind B2 · utility
0Cited by
17References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 13, 2011 |
| Grant date | May 12, 2015 |
| Priority date | — |
| Expiry date | Apr 16, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/021
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.